Berlin Biotech Startup Cellbricks Raises €10M to Advance Living Tissue Implants

Cellbricks Therapeutics, a Berlin-based biotech startup, has secured €10 million in fresh funding to accelerate the development of living tissue implants.

The round includes a €7 million seed investment, led by Silicon Roundabout Ventures, alongside contributions from SPRIND and existing investors like ACT Venture Partners. An additional €3 million+ in non-dilutive funding is currently under negotiation.

The company is advancing toward clinical applications of biofabricated, vascularized tissue implants. Plans include multiple preclinical animal studies to validate functionality and integration in the human body. “These studies are critical for demonstrating how artificial tissues can restore both form and function in reconstructive surgery and wound healing,” a representative noted.

Cellbricks’ immediate focus is on reconstructive surgery, wound healing, and trauma care, where existing treatments often fall short. Its lead program centers on adipose (fat) tissue implants, designed as a biological alternative to synthetic options—particularly in breast reconstruction. “Our goal is to not only replicate tissue structure but also restore its natural function,” the team explained.

Long-term, Cellbricks aims to pioneer 3D-printed human organs, though this remains a multi-step journey. The company’s proprietary biofabrication platform enables the production of complex, vascularized human tissues—a breakthrough for future medical applications. “This technology bridges the gap between vision and clinical reality,” Cellbricks stated.

With operations expanding in Berlin and Boston, the company is poised to drive international research and development. The new funding marks a pivotal shift from technological promise to clinical validation, with a focus on generating robust data for human use.